COVID-19 以éãä»ãŸã§ä»¥äžã«æ±ããããããã«ãªãã®ã¯ç°å¢ã«é¢ãããªãŒããŒã·ãã: ãã®æºåã®ããã«ç¥ã£ãŠããã¹ãããš
ã»ãã®æ°ãæã§ãCOVID-19 ã¯äžçãå€ããŸãããæ°åã³ãããŠã€ã«ã¹ã®ææãæ¡å€§ããããã人ã ã¯èªå® ã«åŸ æ©ãããœãŒã·ã£ã«ãã£ã¹ã¿ã³ã¹ãå®ãããã«ãªããŸãããäžæ¹ãå€æ°ã®äŒæ¥ã¯å¶æ¥ãåæ¢ããäžççµæžã¯åæ»ããŠããŸãã
çŸç¶ã§ã¯ãCOVID-19 ããã€ãŸã§ç§ãã¡ã®çŸåšã®ç掻ã«åœ±é¿ãåãŒãç¶ããã®ãã¯åãããŸããããããããã§ã«çµæžãç§ãã¡ã®ç掻ããããŠç°å¢ãªã©ãå€ãã®é åã«åœ±é¿ãåãŒããŠããããšã¯ééããããŸãããCOVID-19 ã¯ãå¥åº·å±æ©ãäžçäžã«ãããããŠãããšãšãã«ãäžçãçŽé¢ããŠããç¶ç¶çãªç°å¢å±æ©ã®äžéšã§ããããŸãããŸããç§ãã¡ã®çµæžãã©ã€ãã¹ã¿ã€ã«ããå°çã®å¥åº·ãšå¯æ¥ã«ã€ãªãã£ãŠããããšãæããŠãããŠããŸãã
ãã³ãããã¯ãçµéšããããããã®å埩ã«ã€ããŠèãå§ããŠããä»ãããžãã¹ãªãŒããŒãç¥ã£ãŠããã¹ããªã®ã¯ãæ éã«èšç»ããã匷åãªç°å¢æŠç¥ã«å¯ŸããæåŸ ãä»ãŸã§ä»¥äžã«é«ãŸã£ãŠãããšããäºå®ã§ããç§ã®ååã§ãã Salesforce ã® Chief Impact OfficerãSuzanne DiBianca ã¯æè¿ã次ã®ããã«è¿°ã¹ãŠããŸãããç§ãã¡ã¯ä»ãæ°ã ã®èª²é¡ã«çŽé¢ããŠããŸãããä»ã«äœãçºçããŠãããã«é¢ä¿ãªãæ°åå±æ©ãçŸå®ãšãªã£ãŠãããä»åŸ 10 幎ã¯ããã«å¯Ÿããè¡åãå¿ èŠã§ãç§ãã¡ã¯ãªãŒããŒãšããŠãçŸåšããã³å°æ¥ã«ããã£ãŠãµã¹ããããªãã£ãç¶ç¶çã«åªå ããæ¹æ³ãèããå¿ èŠããããŸããSalesforce ã§ã¯ãCOVID-19 ã®å±æ©ã®ãã ãªãã§ãã¹ããŒã¯ãã«ããŒãã³ãã¥ããã£ãåŸæ¥å¡ãããç°å¢ã«å¯ŸãããªãŒããŒã·ããããã³ã¢ã¯ã·ã§ã³ãæ±ãã声ãããæ確ã«ãªã£ãŠããŸããã
æ°åå€åã®åé¡ã«å¯Ÿãã Tableau Foundation ã®åãçµã¿ã®è©³çŽ°ã«ã€ããŠã¯ãã¡ããã芧ãã ããã
ãªãŒããŒãã¡ã¯ããªã¢ãŒãã¯ãŒã¯ã®æšæºåãç°å¢ã«é æ ®ãã亀éæ段ã®å¥šå±ãæç¶å¯èœãªèª¿éããµãã©ã€ãã§ãŒã³ãã©ã¯ãã£ã¹ãç°å¢å埩ã«é¢ããåãçµã¿ãžã®è³éæäŸãªã©ã«ã€ããŠãä»ããç©æ¥µçã«èãå§ããå¿ èŠããããŸããçŸåšã®ç¶æ³ããé£èºããŠããããã«æãããããããŸããããããã§ã¯ãããŸãããå°çã®å¥åº·ã¯ãäžçäžã®äººã ãšäŒæ¥ã®å¥åº·ãšçŠç¥ã«å¯æ¥ã«é¢é£ããŠããŸãã匷åãªæŠç¥ãšææ決å®ã§ãããã«å¯ŸåŠããããšæºåããŠãããªãŒããŒã¯ãä»åŸã®æåã«åããŠãã®ããžãã¹ãšåŸæ¥å¡ãæŽããŠããããšã«ãªããŸãã
ããã§ã¯ãç¥ã£ãŠããã¹ãããšã®è©³çŽ°ãæãäžããŠèª¬æããŸãããã
ç°å¢ã«é¢ãããªãŒããŒã·ãããä»ãŸã§ä»¥äžã«éèŠã«
ãµã¹ããããªãã£ã¯ããæ°å¹Žã§æ¥éã«åºãã£ãŠãããããžãã¹ããã³ãªãŒããŒã·ããæŠç¥ã¯ãããåæ ããŠããŸãã2019 幎㫠Deloitte 瀟ãå®æœãã調æ»ã§ã¯ã調æ»å¯Ÿè±¡ãšãªã£ãäŒæ¥ã® 63% 以äžããªãœãŒã¹ããã³ãµã¹ããããªãã£ã«é¢ããæ£åŒãªç®æšãèšå®ããŠããã3 åã® 2 以äžã¯é¡§å®¢ããç°å¢ã«å¯Ÿããåãçµã¿ãå¢ããããã«ãšãã声ãèããŠãããšã®ããšã§ãããŸãããã®1幎ã§ãæ°åå€åãžã®å¯Ÿçãæ±ããã¹ãã©ã€ãã Amazon ãªã©ã®äŒæ¥ã§å±éãããŠãããåŸæ¥å¡ããã®èŠæ±ããŸããŸãé«ãŸã£ãŠããŸãã
COVID-19 ãåããŠãäŒæ¥ãå ¬éžãããæ¿åºèªæ²»äœé¢ä¿è ã¯å ±ã«ãçµæžãæ¿æ²»ã察人é¢ä¿ãªã©ãå€ãã®åé¡ãžã®å¯ŸåŠã«èžã¿åºãå¿ èŠã«è¿«ãããŠããŸããåœé£ç°å¢èšç»ãã£ã¬ã¯ã¿ãŒã® Inger Andersen æ°ãè«èª¬èšäºã«æžããŠããããã«ãç°å¢ã®ãµã¹ããããªãã£ã«é¢ãããªãŒããŒã·ãããžã®èŠæ±ã¯ä»åŸå¢ããŠããã§ããããAndersen æ°ã«ãããšã人éã®æŽ»åã«ãã£ãŠãã§ã«å°çäžã®ããã 75% ãå€åããŠãããããã«ãã£ãŠ COVID-19 ãªã©ã®åç©ç±æ¥ã®ææçãžã®æé²ãå€§å¹ ã«å¢å ããŠããŸããæ°åå€åãžã®ç Žå£ç圱é¿ã«ã€ããŠã¯èšããŸã§ããããŸããã
ãã®é²ãã¹ãéãæ£ãããã©ããã¯ããªãŒããŒã«ããã£ãŠããŸãããä»ããã森æãå埩ãããäŒæ¡ããããä¿è·é åã®ç®¡çã«æè³ãã森æç Žå£ã«å¯äžããªã補åãåžå Žã«æšé²ããã¹ãæã§ããéççç©ã®ååŒãåæ³çãªå Žæã§ã¯ãè¡çç¶æ ãæ¹åããããã«åªããåãçµã¿ãè¡ãå¿ èŠããããŸãããããŠãã¡ãããå šäžçã«ãã㊠4 çªç®ã«å€ãç¯çœªã§ããéççç©ã®éæ³ååŒã«ã¯ãç·æ¥ã«å¯ŸåŠããå¿ èŠããããŸãããšãAndersen æ°ã¯è¿°ã¹ãŠããŸãã
çŸåšã®ãã³ãããã¯ã®çµæ¯åŸãäžçã®ãªãŒããŒãã¡ã«ããææ決å®ã®æéãšãªãã®ã¯ãå°çã®å¥åº·ãšäººéã®å¥åº·ã®éã®ã€ãªããã§ãããæé·ã®ãšã³ãžã³ãåã³ãã®å転ãäžãå§ããã«ã€ããŠãè¯èçãªèªç¶ç®¡çãã©ã®ããã«ããŠãããããã®ãç°ãªãçµæžãã®äžéšãšãªãåŸããèŠãŠããå¿ èŠããããŸããä»åŸå¿ ç¶çã«åºçŸãããç°ãªãçµæžããšã¯ãç°å¢ã«ããããä»äºãæé·ãç°ãªãç掻æ§åŒãè³éãšè¡åã«ãã£ãŠæšé²ãããçµæžã®ããšã§ãã人ã ã®å¥åº·ãšå°çã®å¥åº·ã¯äžäœã§ãããäž¡æ¹ãšãåãæ段ã«ãã£ãŠç¹æ ãããããšãã§ããŸããã
COVID-19 ã瀺åããŠããã®ã¯åŒ·åãªãµã¹ããããªãã£ããªã·ãŒã®å¿ èŠæ§
ããã§ä»ããã®ãã³ãããã¯ã®åŸãå°çãšäººã ã®å¥åº·ã確ä¿ããããã«ãªãŒããŒãã¡ã¯ã©ã®ãããªã¹ããããé²ããŠããã¹ãã§ãããã?
COVID-19 ã¯ãã§ã«ãäžçäžã®å€ãã®äŒæ¥ã®éå¶æ¹æ³ã厩å£ãããŸãããã»ãã®æ°é±éã§åŸæ¥å¡ã¯ãªã¢ãŒãã¯ãŒã¯ã匷ããããããã«ãªãããªãã£ã¹ã¯ééãããéå€ã¯äžæçã«åæ¢ãããŸããããªãŒããŒãã¡ã¯ããããã®å€åã«é¢ããŠäººã ãå°ããšããææŠã«ç«ã¡äžãããªããã°ãªããŸããã§ããããããŠä»ããã®å€ãã¯æ°ããéå¶æ¹æ³ã«èœã¡çãå§ããŠããŸãã
ãããã®ã·ããã¯ãŠã€ã«ã¹ã®æ¡å€§ã¹ããŒããé ãããã®ã«å¹æçã§ããããšã蚌æãããŠããŸããããã 1 ã€ã®å¹æããããŸããããã¯ãå°çã«äŒæ¯ãããããããããšã§ããææè æ°ãæ¥å¢ããå€æ°ã®åœã§èªå® åŸ æ©ãå€åºçŠæ¢ä»€ãå®æœããããšãæ±æã¬ãã«ãæ±æç©è³ªã®æåºéãå€§å¹ ã«äœäžããŸãããããã¯æææ¡å€§ãæåã«èµ·ããäžåœã§èŠããããŸãäžçäžã®åœã ãéœåžã§èŠãããŠããŸãã
äžåœã«ããããã®è©³çŽ°ã¯æ¬¡ã®ãããªãã®ã§ãã
è¡æããã®ä»ã®é éæ€åºè£ 眮ããã®ããŒã¿ã§ã¯ãç¹ã«éœåžãªã©ã® COVID-19 ãæ¡å€§ããå°åã§äºé žåççŽ æåºéã倧æ°æ±æãæžæ»ã亀éæ©é¢ã«ããæ±æç©è³ªæåºãã»ãŒãªããªããŸããã人ã ãèªå® ã«åŸ æ©ããäžèŠäžæ¥ã®å Žåãé€ããŠå€åºããªãããã«èšãããŠããå°åã§ã¯ãæ±æã亀éé¢é£ã®æåºéã®ããŒã¿ (éåžžã枩宀å¹æã¬ã¹æåºéã®çŽ 14% ãå ããŠãã) ãæ¥æ¿ã«æžå°ããŠããŸãã
ã¹ã¿ã³ãã©ãŒã倧åŠã®ææã§ãããã°ããŒãã«ã«ãŒãã³ãããžã§ã¯ãã®è°é·ã§ãã Rob Jackson æ°ã¯ Grist èªã§ãCOVID-19 ã«ãã£ãŠéå»åäžçŽã§åããŠã®å€§ããªæåºéäœäž (çŽ 5%) ãããããããå¯èœæ§ã¯äºå®ã ãããã®ãããªæ¹æ³ã§éæãããã£ãããã§ãªããšèªã£ãŠããããäœçŸäžãã®å€±æ¥è ãåºããŠæåºéãæžããããããã§ã¯ãããŸããããšè¿°ã¹ãŠããŸãããããããã®åæžãç¶ãå¯èœæ§ã¯äœãã§ããããäžåœã®ããŒã¿ã«ç€ºãããŠããéããå€åºèªç²ã解é€ãå§ããå°åã§ã¯ããã«æåºéãåã³å¢ããå¯èœæ§ãé«ããšæãããŸãã
COVID-19ãæ°åãããã³ããŒã¿ã亀ããé åã«é¢ããå ±éã«ã€ããŠã¯ãGrist.org ãã芧ãã ããã
éåžžã©ããã«ããžãã¹ãè¡ããããŸãã¯å°çãæãã®ãããã®äºæã®ç¶æ³ã«é¥ãããã¯ãããŸãããæåºéãåæžããããšã¯å¯èœã§ãããšããæ確ãªæŠå¿µå®èšŒããããŸããä»ãããžãã¹ãªãŒããŒãèããŠããããšã¯ããã³ãããã¯çµæ¯åŸã«æ±æãåã³é«ãŸã£ãŠããŸãããªããŠã³ããå¹æãåé¿ããããã§ã®èªèº«ã®åœ¹å²ã§ãã
ããã«é¢ããŠãããžãã¹ãªãŒããŒã«ã¯ããã€ãã®çåãæµ®ãã³ããã®å¯Ÿçãæµ®ãã³äžããã§ãããããããã®å¯Ÿçã¯ãå€ãã®ãªãŒããŒãå¥ã®èŠ³ç¹ãåºã«ããŠæ°é±éåã«ãè¿ éã«ç§»è¡ãããã®ã§ããåŸæ¥å¡ãåšå® å€åãšãªããéå€ãæåºéãåæžããããªãã£ã¹ããã«çšŒåãããªãããšã®åœ±é¿ãç¥ãããšãã§ããä»ãç§ãã¡ã¯ãã³ãããã¯çµæ¯åŸãå°çãä¿è·ããããã«ã©ã®ãããªããªã·ãŒãå®æœã§ããã§ãããã?
ããžãã¹ãªãŒããŒã¯ä»ãCOVID-19 ããåŠãã æ å ±ãåºã«ãæ°åã«å¯Ÿããèªç€Ÿã®ã¢ã¯ã·ã§ã³ãã©ã³ãã©ã®ããã«ãããã«ã€ããŠæ€èšãå§ããã¹ãæã«æ¥ãŠããŸããå¯èœãªå Žåãå šç€Ÿã§æ確ãªåšå® å€åããªã·ãŒãçå®ã§ããŸãã? èªè»¢è»éå€ãå ¬å ±äº€éæ©é¢ãªã©ãç°å¢ã«ãããã亀éæ段ã奚å±ããŠéå€ã«ããæåºéãäœãæããããã«ããªãŒããŒãšããŠäœãã§ããŸãã? èªç€Ÿã®ãã«ãæé«ã®å¹çæ§ã§éå¶ãããŠããããšãä¿èšŒããããã«ããã«ã®ç£æ»ãå®æœã§ããŸãã?
æ¿çã®çå®è ãå ¬éžãããæ¿åºèªæ²»äœé¢ä¿è ã«å¯ŸããŠäžçéè¡ãè¿°ã¹ãŠããããšã¯ããã³ãããã¯çµæ¯åŸã®äž»ãªãã©ãŒã«ã¹ã® 1 ã€ã¯ãäžçããã³ãã®çµæžã®é·æçãªå®å®åã«ãªããšããããšã§ããã€ãŸããåç³çæãžã®äŸåããåçå¯èœãšãã«ã®ãŒã«ã·ããããããã«è£å©éãåèšèšããæç¶å¯èœãªäº€éã€ã³ãã©ãšç°å¢ä¿®åŸ©ãããžã§ã¯ãã«å€å€§ãªæè³ãè¡ãããšã§ãã
ãããã¯ã»ã¯ã¿ãŒå šäœã§çèãã¹ã倧ããªã·ããã§ããããããã³ãããŠã€ã«ã¹ã¯ãã§ã«éåžžã®ããžãã¹ãäžå€ãããŠããŸãããªãŒããŒãã¡ã¯å°æ¥ã«ã€ããŠããŸãæ°ããç掻æ§åŒã®äžã§æåãåããããããã«æºåããæ¹æ³ã«ã€ããŠèããå¿ èŠããããŸãã
ããžãã¹ãªãŒããŒãå°çã®å¥åº·ãžã®æè³ã§ã§ããããš
ä»ããªãŒããŒãšããŠéèŠãªã®ã¯ãçµç¹å ã§ç°å¢ã«é¢ãã匷åãªããªã·ãŒãå®æœããããã«äžæ©èžã¿åºãããšã§ãããªãŒããŒãã¡ã¯ä»ãŸã§ä»¥äžã«ãäŒç€Ÿã®æ ãè¶ ããŠå°çã®å¥åº·ãšçŠç¥ã®ããã«åãçµãã§ããŸãã
éå»æ°å¹ŽéãäŒæ¥ãšæè³å®¶ã«ããç°å¢ã®ãµã¹ããããªãã£æ¯æŽå¯Ÿçã¯å¢å ãç¶ããŠããŸãã2015 幎ã«åœé£ãæ¡æããæç¶å¯èœãªéçºç®æš (SDG) ã«ãããå€ãã®äŒæ¥ã¯å°çå šäœã®å¹žçŠã«å¯äžããè²¢ç®è ãšããŠããŸãããžãã¹ãšããŠããã® 17 ã®ç®æšãèªç€Ÿã®éå¶ã®è©äŸ¡ããã³æ¹åæ¹æ³ãšããŠæ¡çšããŸããããã㊠2018 幎ãPwC ã®ã¬ããŒãã«ãããšãäŒæ¥ã® 50% 㯠SDG ã®ããã€ããåªå äºé ãšããŠéžæãã27% ã¯èªç€Ÿã®ããžãã¹æŠç¥ã«ãããã®ç®æšãçµã¿èŸŒãã§ããŸããç±³åœã®å€§äŒæ¥ 250 瀟㮠90% 以äžã¯ãäŒæ¥ã®ãµã¹ããããªãã£ã¬ããŒããäœæããŠããŸããäŒæ¥ãããã®ããžãã¹ç¯å²ãè¶ ãããããã®ç®æšã«å¯ŸããŠåãçµãã§ããããšã瀺ããããšãä»ãŸã§ä»¥äžã«éèŠã«ãªã£ãŠããŸãããããã®ç®æšã¯å°çã®é·æçãªå¥åº·ã«ãšã£ãŠäžå¯æ¬ ã§ãã
ãã㯠COVID-19 以åã«ãåœãŠã¯ãŸã£ãŠããŸãããããã³ãããã¯çµæ¯åŸã¯ããã«å«ç·ã®åé¡ãšãªããŸããæ°åã³ãããŠã€ã«ã¹ã®åºçŸã¯ã森æäŒæ¡ããã®ä¿é²èŠå ã ã£ãããšãããŒã¿ã§ç€ºãããŠããŸããã€ãŸãã人éã®ç£æ¥ã掻åãåºãããèªç¶ã®ãšã³ã·ã¹ãã ã䟵害ãå§ããŠãããããåç©ãšäººéã®éã§ã®ãŠã€ã«ã¹ã®çžäºæ±æã®æ©äŒãæ¥å¢ããŠããã®ã§ããèªç¶è³ç£ã®ç Žå£ã倧ããçž®å°ãããã§ã«å€±ã£ããã®ãåçãããããã«äœãããªããã°ãçŸåšã®ç¶æ³ãç¹°ãè¿ãããšã«ãªããŸãã
ããžãã¹ãªãŒããŒã¯ãCOVID-19 ãšç°å¢æªåã®éã®ã€ãªãããããµã¹ããããªãã£å¯ŸçããµããŒãããããã®è¡åãèµ·ãããã£ãããšããå¿ èŠããããŸããåŸæ¥å¡ãšæè³å®¶ã¯ã©ã¡ããããŸããŸãããžãã¹ãªãŒããŒã«ãµã¹ããããªãã£ãžã®åãçµã¿ãè¡ãããèŠæ±ããããã«ãªã£ãŠããŸããããŒããŒãããžãã¹ã¬ãã¥ãŒ (HBR) èª ã¯ 2019 幎ãäž»èŠãªæè³å®¶ã«ãšã£ãŠãµã¹ããããªãã£ã¯ã»ãŒæ®éçãªãæåªå äºé ãã§ãããšå ±åããŠããŸããäŒæ¥ã«ãšã£ãŠãå°çãä¿è·ããããã«ãªãœãŒã¹ãæè³ããæ©äŒã¯ãããŸã§ã«ãªãå¢ããŠããŸããããšãã°ãSalesforce ã® CEO ã§ãã Marc Benioff ã¯ç°å¢ã®æ倱ãç·©åããããã«å°çå šäœã« 1 å æ¬ã®æšãæ€æš¹ããåãçµã¿ãæ¯æããŠããŸãããã㊠CIO ã® DiBianca ã¯ãSalesforce ãã¯ä»å¹Žã®ã¢ãŒã¹ããŒãèšå¿µããŠã5 äžæ¬ã®æšãæ€æš¹ããããšãèªçŽãããšè¿°ã¹ãŠããŸãããªãŒããŒãã¡ã«ãšã£ãŠããã®ãããªåç掻åã«åå ããããšãããã³ãµãã©ã€ãã§ãŒã³ã«ãããŠãããªãç°å¢ç Žå£ãå¶éãããšèªçŽããããšã¯ã人ã ãšå°çã®é·æçãªå¥åº·ã®ç¢ºä¿ã«åããŠåãçµãã§ããããšã瀺ãæ¹æ³ãšãªããŸãã
COVID-19 ã¯ãå人ãäŒæ¥ãããã³ã³ãã¥ããã£ãšããŠãç§ãã¡ã®è¡åãæ¯æ¥ã©ãã»ã©ã®åœ±é¿ãå°çã«äžããŠãããã瀺ããŠããŸãããŸããç§ãã¡ãä»ããè¡åãèµ·ãããªãéããèªåãã¡èªèº«ãä»åŸãããªãè åšã®ãªã¹ã¯ã«ããããŠãããšããããšããæ確ã«ç€ºããã®ã§ããä»ãããžãã¹ãªãŒããŒã«ã¯ããããã®æèšãçµ±åããèªç€Ÿã®ãªãã¬ãŒã·ã§ã³å ã§ãããã³æ¿åºã NPO ãšé£æºãããäºãã«ååããããšã§ããµã¹ããããªãã£èšç»ã«ãã£ãŠãã®å±æ©ããæãåºãããã®æŠç¥ãå®æœãããšããæ©äŒãäžããããŠããã®ã§ãã
é¢é£ã¹ããŒãªãŒ
Subscribe to our blog
Tableau ã®ææ°æ å ±ãã¡ãŒã«ã§ãç¥ããããŸã